Metoclopramide (1a), possessing a dopamine D 2 receptor antagonist and weak serotonin 5-HT 4 receptor agonist activities, 1a) is used clinically as a gastrointestinal prokinetic and an antiemetic agent. 1b) However, its clinical application is limited due to its side effects, such as extrapyramidal syndrome, parkinsonism and elevated serum prolactin levels, caused by blockage of the dopamine D 2 receptor.
Metoclopramide (1a) , possessing a dopamine D 2 receptor antagonist and weak serotonin 5-HT 4 receptor agonist activities, 1a) is used clinically as a gastrointestinal prokinetic and an antiemetic agent.
1b) However, its clinical application is limited due to its side effects, such as extrapyramidal syndrome, parkinsonism and elevated serum prolactin levels, caused by blockage of the dopamine D 2 receptor.
We previously reported that the introduction of a methylenephenoxy group between the benzamide moiety and the terminal aminoalkyl groups of 1a led to the discovery of itopride (2) , with an appropriate dopamine D 2 receptor antagonist activity and a distinctive acetylcholine esterase inhibitory activity. 2) On the other hand, we suggested that amphoteric-ionization would be a useful approach to discovering a new drug, and actually succeeded in finding selective histamine H 1 antagonists by applying this method to classical antihistaminics. 3) We initially applied the amphoteric-ionization to 1a in order to find a new type of gastrointestinal prokinetic agent. Although we preliminarily synthesized an amphoteric-ionized compound (3) by the introduction of an alkanecarboxylic acid moiety onto the terminal nitrogen atom of 1a, it had no significant gastrointestinal prokinetic activity. Cisapride (1b), 4) which has a conformationally restricted amino moiety in comparison with 1a, has been found to show more potent gastrointestinal prokinetic activity than 1a. We therefore expected that some kind of conformational restriction of 3 would lead to an increased gastrointestinal prokinetic activity, and designed a series of [[(4-amino-5-chloro-2-methoxybenzoyl)amino]cycloamino]alkanecarboxylic acid derivatives (4) .
In this paper, we describe the synthesis and gastrointestinal prokinetic activity of a series of [[(4-amino-5-chloro-2-methoxybenzoyl)amino]cycloamino]alkanecarboxylic acids (4) . We also discuss conformational effects on gastrointestinal prokinetic activity and the evaluation of ester prodrugs of 4-[(4-amino-5-chloro-2-methoxybenzoyl)amino]-1-piperidineacetic acid (19), which exhibited the most excellent gastrointestinal prokinetic activity.
Chemistry New amphoteric compounds (19-24, 32a-c, 38, 43d-f) and prodrugs (44-60) of compound 19 were synthesized as shown in Charts 2-6.
As shown in Chart 2, benzamides (19-24) with 1-piperidinealkanecarboxylic acid side chains were prepared by method A. Firstly, 4-amino-1-benzylpiperidine (5) was treated with trifluoroacetic anhydride to give 6. Catalytic hydrogenolysis of 6 with Pearlman's catalyst, followed by condensation with trytyl chloride, afforded 8 via 7. Then deacylation of 8 with KOH gave 4-amino-1-tritylpiperidine (9) . Commercially available 4-amino-5-chloro-2-methoxybenzoic acid (10) was condensed with 9 to afford 11. Deprotection of 11 with hydrochloric acid gave the secondary amine (12), 5) which was treated with ethyl or methyl w-bromoalkanecarboxylates, ethyl 2-bromopropionate or ethyl acrylate, to afford various esters (13) (14) (15) (16) (17) (18) . The esters (13) (14) (15) (16) (17) (18) were hydrolyzed under basic conditions to provide the desired amphoteric benzamides (19-24). Benzamides (32a-c), possessing endo-or exo-9-azabicyclo[3.3.1]nonane-9-acetic acid, or an exo-8-azabicyclo-[3.2.1]octane-8-acetic acid side chain, were prepared by method B as shown in Chart 3. 4-Acetylamino-2-methoxybenzoic acid (25) 6) was converted with ethyl chloroformate to the activated ester, which was condensed with endo-or exo-3-amino-9-benzyl-9-azabicyclo [3.3 .1]nonane (26a, b) 7) or exo-3-amino- 8-benzyl-8-azabicyclo [3.2 .1]octane (26c) 7) to afford benzamides 27a-c. Catalytic hydrogenolysis of 27a-c with Pearlman's catalyst gave secondary amines 28a-c, and the subsequent treatment with ethyl bromoacetate afforded compounds 29a-c. Chlorination of 29a-c with sulfuryl chloride yielded 30a-c, which was deacetylated with hydrochloric acid to give compounds 31a-c. Basic hydrolysis of 31a-c afforded the desired amphoteric benzamides (32a-c).
Benzamide (38), with an endo-8-azabicyclo [3.2. 1]octane-8-acetic acid side chain, was synthesized by method C as shown in Chart 4. Treatment of endo-4-acetylamino-5-chloro-2-methoxy-N-(8-methyl-8-azabicyclo[3.2.1]oct-3-yl)benzamide (33) 7) with methyl chloroformate gave urethane (34), which was exposed to trimethylsilyl iodide to yield 35. Compound 35 was treated with ethyl bromoacetate to afford 36, which was subsequently deacetylated with hydrochloric acid to obtain ester (37). Compound 37 was hydrolyzed with base to provide the desired amphoteric benzamide (38).
Heterocyclic carboxamides (43d-f), each possessing an amphoteric side chain, were prepared by method D as shown in Chart 5. Acid chloride (39d-f) 8, 9) was condensed with amine (26a) to afford amides (40d-f). Catalytic hydrogenolysis of 40d-f with Pearlman's catalyst, followed by conden-sation with ethyl bromoacetate, afforded esters (42d-f) via secondary amines (41d-f). The esters (42d-f) were subsequently hydrolyzed with base to give the desired amphoteric carboxamides (43d-f).
The ester prodrugs (44-60) of 19 were prepared by method E as shown in Chart 6. Compound 19 was esterified with alcohol using an acid catalyst, or with various halides in N,N-dimethylformamide (DMF) in the presence of potassium carbonate, to give the desired prodrugs (44-60).
Physicochemical data for compounds 13-24, 28a-c, 29a-c, 30a-c, 31a-c, 32a-c, 36-38, 42d-f, 43d-f and 44-60 are given in the Experimental section or in Tables 1-4. 
Results and Discussion
The gastrointestinal prokinetic activities of all amphoteric compounds (19-24, 32a-c, 38, 43d-f) in conscious dogs were determined using the method of Z. Itoh. 10) The gastric antrum motility of each compound was quantified by determining a motor index, which was equivalent to the integrated area between the contractile wave and the base line, and expressed as a symbol based on a percentage against the basal motor index. Colonic motility was expressed by the % ratio of the number of dogs, in which the giant contraction on the ascending colon was observed, versus the tested dogs. The dopamine D 2 receptor binding affinity, which was responsible for the side effect of benzamides, such as 1a and 1b, was estimated and expressed by pIC 50 (-logarithm of inhibitory concentration 50%) values. The pharmacological results are given in Tables 5-7 .
Firstly, we examined monocyclic amino compounds (Table  5 ). Amphoteric compounds (19-23) with a straight methylene chain, except for 22, showed more potent gastro-and colon-prokinetic activities than N-methyl analog (61) 11) or 1a, and elongation of the methylene chain led to a decrease in both prokinetic activities. Compound 19 especially exhibited excellent gastro-and colon-prokinetic activities in comparison with 1b. In addition, the introduction of a methyl group (24) into the a-position of the carboxy group in 19 led to a slight reduction in gastro-and colon-prokinetic activities. These results suggested that the distance between the basic nitrogen atom and the carboxy group would be an important factor for gastro-and colon-prokinetic activities.
The dopamine D 2 receptor affinity of the N-methyl analog (61) was moderate (pIC 50 ϭ5.7), while none of the amphoteric compounds showed significant affinity. This result suggested that amphoteric-ionization caused a decrease in D 2 binding affinity.
We selected the acetic acid moiety (nϭ1) as a substituent on the basic nitrogen atom for further optimization, since 19 exhibited the most excellent gastro-and colon-prokinetic activities among monocyclic amphoteric compounds (19-24).
Secondly, we addressed our attention to the compounds with a bicyclic amine moiety. As shown in Table 6 , bicyclic amphoteric compounds (32a-c, 38) showed similar or less potent gastro-or colon-prokinetic activity in comparison with the corresponding N-methyl analogs (62-65) 7) in contrast to the case of monocyclic compounds. Especially, 32b
April 2001 429 a) The symbols have the following meanings: ϩϩ, 150% or more; ϩ, 125% to 150%; Ϫ, less than 125%; NT, not tested. b) % ratio of number of dogs in which giant contraction was observed versus the tested dogs. showed no significant gastro-and colon-prokinetic activities. Concerning D 2 binding affinity, bicyclic amphoteric compounds (32a-c, 38) showed less potent affinity than the corresponding bicyclic N-methyl derivatives (62-65), and amphoteric-ionization of bicyclic compounds was found to cause the decrease in dopamine D 2 affinity. This observation was consistent with the previous result obtained from monocyclic compounds. Also examined were the replacements of the benzene ring of 32a, the most potent gastro-and colon-prokinetic active compound among the bicyclic amphoteric compounds, by some heterocyclic rings (Table 7) . These replacements caused the disappearance in both gastrointestinal prokinetic activity and dopamine D 2 affinity in not only N-methyl analogs (66-68) but also the corresponding amphoteric compounds (43d-f). Consequently, the benzene ring of 32a seemed to be essential for the gastrointestinal prokinetic activity.
On the basis of the above screening results, 19, with an amphoteric monocyclic side chain, was selected as the candidate for a novel gastrointestinal prokinetic agent, exhibiting both the gastro-and colon-prokinetic activities without D 2 binding affinity. Furthermore, we examined its penetration into the central nervous systems (CNS). As shown in Table 8 , 19 showed a 100 times lower brain/plasma ratio than 1b and thus amphoteric-ionization was also found to be effective in lowering the penetration into the brain. Accordingly, 19 was expected to show no significant CNS side effect.
5-HT 4 Receptor Agonist Activity and Conformational Analysis
In order to clarify the mode of action for 19, the influence of the selective 5-HT 4 antagonist, SB-207266, 12) on the gastric and colonic contractions induced by 19 was evaluated. As shown in Table 9 , the selective 5-HT 4 antagonist blocked both gastric and colonic contractions. This result suggested that the 5-HT 4 receptor agonist activity would participate in the mechanism for the gastrointestinal prokinetic effect of 19.
The result shown in Table 9 allowed us to examine the relationship between gastrointestinal effects and 5-HT 4 agonist activity by conformational analysis.
Serotonin 5-HT 4 agonist activity of 19, 24, 32a-c and 38 was evaluated by their effects on carbachol-induced tone in rat esophagus and expressed as the negative logarithm of the molar concentration that exhibited 50% relaxation to the carbachol-induced contraction (pEC 50 ), as shown in Table 10 .
On the other hand, we implemented the conformational analysis of 19, 24, 32a-c and 38 according to the method of López-Rodríguez et al. 13) The molecules were built de novo in their protonated forms, which are believed to be bioactive forms, using the CAChe system, 14) and their geometry was optimized by the MM2 force field of the CAChe system. For the first purpose, we applied a systematic conformational analysis around four rotatable bonds, as shown in Fig. 1 , and calculated the energy by 15°stepwise increments of the dihedral angles. Then the lower energy conformers of each compound were energy-minimized by the MM2 force field. We tried to identify the lowest energy conformer of each compound accordingly. Generally, the oxygen atom substituted at 430 Vol. 49, No. 4 
See footnote a and b in Table 5 . (4) the basic nitrogen atom deviated at a distance of 3.6-4.0 Å from the plane of the benzene ring (h). To identify the active conformation, we actually performed a conformational analysis and energy minimization of each compound around the dihedral angle (q), defined by [C3-N5-C6-C7] (see Fig. 1 ) of each compound, by 1°stepwise increments of the dihedral angle, and then examined to see if the selected conformers of each compound were adapted to four structural criteria in the pharmacophore model, as described above. Except for the deviations (the criterion 4); h), the structural parameters of 19, 24, 32b and 32c corresponded well with the above three criteria (1 to 3) of the 5-HT 4 pharmacophore model, but the 5-HT 4 agonist activity of 24, 32b and 32c was weaker than that of compound 19. The a-methyl group of 24 and the alkylene-bridged chains of exo-bicyclic compounds (32b, 32c) were presumed to situate at the same side of their amide carbonyl groups and which might disturb the tight interaction in the binding mode between the ligand and 5-HT 4 receptor for enhancing 5-HT 4 agonist activity (see Fig. 3 ). The distances Ar-N of endo-bicyclic compounds (32a, 38) were also found to be shorter than that of monocyclic compound (19), and it seemed to be one of the reasons they showed weak 5-HT 4 agonist activity in comparison with 19. On the other hand, 5-HT 4 agonist activities of all amphoteric compounds almost correlated with their in vivo gastrointestinal prokinetic activities. This result suggested that 5-HT 4 agonist activities of amphoteric compounds could contribute to their in vivo gastrointestinal prokinetic effects. Compound 19, however, exhibited excellent in vivo gastrointestinal prokinetic activity after intravenous administration in dogs in spite of weaker 5-HT 4 agonist activity than 1b (pEC 50 ϭ7.26).
15) Therefore, it was considered that other mechanisms contributed to the gastrointestinal activity of 19.
Examination of Prodrugs of Compound 19 As described above, compound 19, with an amphoteric monocyclic side chain, was selected as a candidate for a novel gastrointestinal prokinetics. Unfortunately, 19 showed only weak gastrointestinal activity by oral administration in further evaluation. It seemed that poor oral absorption of 19 was attributed to its low lipophilicity. On the other hand, the ethyl ester (13), its synthetic precursor, had potent gastrointestinal activity after oral administration, but an undesired emetic side effect was observed. We therefore set about examining the other various ester prodrugs of 19.
We tested for the gastrointestinal prokinetic and emetic action as well as the physicochemical and metabolic stability of the prodrugs. Their results were summarized in Table 11 .
Among the double ester type of prodrugs (57-60), 58 showed the best pharmacological effect, but its physicochem- ical stability was not so good. Although benzyl ester (53) and alkyl esters, having functional groups (54-56), showed no emetic action, they had only moderate gastrointestinal prokinetic action. Methoxyethyl ester (52) showed good pharmacological actions but it was expected to be tolerant to hydrolysis. Among straight or branched alkyl esters (44-51), nbutyl (46) and n-pentyl (47) esters were preferable in terms of pharmacological and pharmacokinetic profiles. We selected the n-butyl prodrug (46), which exhibited the most potent gastrointestinal prokinetic activity, as a developing candidate.
Compound 46 also did not show the emetic side effect after oral administration in dogs. After oral administration of 46 (10 mg/kg) in rats, only 19 was detected in plasma. Accordingly, 46 was expected to exhibit excellent gastrointestinal prokinetic activity without significant CNS or emetic side effects.
Conclusion
1) The combination of amphoteric-ionization and cyclization of the terminal amine moiety of 1a caused an increase in gastro-and colon-prokinetic activities and a decrease in dopamine D 2 receptor affinity. This combination seemed to be an effective approach to a selective gastrointestinal prokinetic activity devoid of other pharmacological activity such as CNS side effects, and also to generating marvelous colon-prokinetic activity.
2) Amphoteric-ionization was also effective for reducing the penetration into the brain.
3) The 5-HT 4 receptor agonist activity of 19 was consid- ered to participate partially in the gastrointestinal prokinetic effect.
4) According to our conformational analyses, the amethyl group in 24 and the alkylene-bridged chain in exo-bicyclic compounds (32b, 32c) were found to be located at the same side of their amide carbonyl groups. These conformations might disturb the interaction in the binding mode between the ligand and 5-HT 4 receptor, leading to their lower gastrointestinal activity.
5) The n-butyl ester (46) of 19 was found to improve oral availability compared to 19, without an emetic side effect.
Further studies of the candidate, the ester 46 (Code No: AU-224), as a new gastrointestinal prokinetic agent for preclinical evaluation, is now in progress, and the mechanism for the active metabolite 19 is also being examined in detail.
Experimental
Chemistry All melting points were measured on a Yanagimoto melting point apparatus and are uncorrected. Spectral data were obtained using the following apparatus:
1 H-NMR spectra with JEOL FX-90Q (90 MHz), JEOL EX-270 (270 MHz) and JEOL A-500 (500 MHz) spectrometers; mass spectra (MS) with JEOL JMS-DX 300 mass spectrometer; IR spectra with Hitachi 270-30 spectrometer. Chemical shifts are expressed as d (ppm) values with tetramethylsilane (TMS) as an internal standard. Column chromatography was carried out with Kieselgel 60 (Merck) or Aluminium oxide 90 (Merck). Elemental analyses were performed using Yanagimoto MT-3 and MT-5 elemental analysis apparatus, and analytical results were within Ϯ0.4% of theoretical values. TLC was conducted on a 0.25 mm pre-coated silica gel plate (60F 254 , Merck), and spots were detected by inspection under short (254 nm) wavelength UV light, or by the colors developed with iodine. Organic extracts were dried over anhydrous Na 2 SO 4 . The solvent was evaporated under reduced pressure.
The following known intermediates and reference compounds were prepared essentially according to the literature: 4-amino-5-chloro-N-[2-(diethylamino)ethyl]-2-methoxybenzamide (metoclopramide 1a), 6) 7) 1-methyl-1H-indazole-3-carbonyl chloride (39d), 8 1H-indole-3-carbonyl chloride (39e), 9) 1-methyl-1H-indole-3-carbonyl chloride (39f), 9) 4-amino-5-chloro-N-(1-methyl-4-piperidyl)-2-methoxybenzamide (61), 11) endo-4-amino-5-chloro-2-methoxy-N-(9-methyl-9-azabicyclo[3.3.1]nonan-3-yl)benzamide (62), 7) exo-4-amino-5-chloro-2-methoxy-N-(9-methyl-9-azabicyclo[3.
Method A. N-(1-Benzyl-4-piperidyl)trifluoroacetamide (6) A solution of 4-amino-1-benzylpiperidine 5 (25.0 g, 131 mmol) and trifluoroacetic anhydride (20.4 ml, 147 mmol) in CH 2 Cl 2 (100 ml) was stirred at room temperature for 30 min. The reaction mixture was concentrated and saturated aqueous NaHCO 3 was added to the residue. The mixture was extracted with CH 2 Cl 2 . The extract was dried and evaporated. The resulting residue was converted to the hydrochloride in the usual way to give the hydrochloride (41.6 g, 98%) of 6 as a colorless crystal, which was recrystallized from AcOEt to give colorless needles, mp 205-207°C. Anal. Calcd For C 14 
4-Amino-5-chloro-2-methoxy-N-(1-trityl-4-piperidyl)benzamide (11)
A mixture of 10 (16.4 g, 81.3 mmol), Et 3 N (13.6 ml, 97.7 mmol) and ClCO 2 Et (8.55 ml, 89.9 mmol) in anhydrous tetrahydrofuran (THF, 330 ml) was stirred under ice cooling. After 2 h, 9 (30.6 g, 89.3 mmol) was added dropwise to the mixture and stirred at room temperature for 20 h. The insoluble substance was filtered off and the filtrate was evaporated. The resulting residue was dissolved in CH 2 Cl 2 . The CH 2 Cl 2 solution was washed with water, dried and evaporated. The residue was washed with n-hexane to afford 39.4 g (92%) of 11 as a colorless crystal, which was used for the next step without further purification. 
4-Amino-5-chloro-2-methoxy-N-(4-piperidyl)benzamide (12)
A mixture of 11 (39.4 g, 74.9 mmol) and concentrated HCl (10 ml) in acetone (600 ml) was refluxed for 40 min. After cooling, the resulting precipitate was collected by filtration and washed with acetone to afford the hydrochloride (25.8 g, 78%) of 12 5) as a colorless crystal, which was recrystallized from EtOH to afford colorless crystals, mp 214-217°C. Anal. Calcd for C 13 
Ethyl 4-[(4-Amino-5-chloro-2-methoxybenzoyl)amino]-1-piperidineacetate (13)
A mixture of the hydrochloride of 12 (3.20 g, 9.91 mmol), ethyl bromoacetate (1.22 ml, 11.0 mmol) and K 2 CO 3 (3.04 g, 22.0 mmol) in DMF (32 ml) was stirred at 60°C for 2.5 h. After evaporation of the solvent, water was added to the residue and extracted with CH 2 Cl 2 . The organic layer was washed with water, dried and evaporated to afford yellow oily residue. The residue was converted to the hydrochloride in the usual manner to afford the hydrochloride (3.31 g, 73%) of 13 as a pale yellow crystal, which was recrystallized from EtOH to afford colorless flakes, mp 196. Compounds 15-18 were prepared in a manner similar to that described above and their physicochemical data were summarized in Table 1 .
Ethyl 4-[(4-Amino-5-chloro-2-methoxybenzoyl)amino]-1-piperidinepropionate (14)
A mixture of 12 (2.79 g, 9.80 mmol) and ethyl acrylate (1.35 ml, 12.5 mmol) in EtOH (28 ml) was refluxed for 4 h. The reaction mixture was concentrated and the residue was washed with iso-Pr 2 O to afford pale yellow crystals (3.34 g, 87%), which were recrystallized from a mixture of acetone and Et 2 85 (1H, m), 3.84 (3H, s), 4.06 (2H, q, Jϭ7.0 Hz), 5.70-5.85 (2H, br s) , 6 .49 (1H, s), 7.60-7.75 (1H, m), 7.66 (1H, s).
4-[(4-Amino-5-chloro-2-methoxybenzoyl)amino]-1-piperidineacetic Acid (19)
A mixture of the hydrochloride of 13 (2.23 g, 5.49 mmol) and 2 N aqueous NaOH solution (9.86 ml) in MeOH (22 ml) was refluxed for 1 h. The reaction mixture was concentrated and the resulting residue was dissolved in a small amount of water. The solution was adjusted to pH 2 with 10% HCl. The resulting precipitate was collected by filtration and washed with water to afford the hydrochloride (1.47 g, 78%) of 19 as a pale brown crystal, which was recrystallized from water to afford pale yellow pillars, mp 248-251°C (dec.). Anal. Calcd for C 15 35 (2H, m), 3.35-3.60 (2H, m), 3.85 (3H, s), 3.85-4.10  (1H, m), 3.98 (2H, s), 6.55 (1H, s), 7.63 (1H, s), 7.65-7.80 (1H, m) .
Compounds 20-24 were prepared in a manner similar to that described above and their physicochemical data were summarized in Table 1 .
Method B. endo-4-Acetylamino-N-(9-benzyl-9-azabicyclo[3.3.1]non-3-yl)-2-methoxybenzamide (27a) A mixture of 4-acetylamino-2-methoxybenzoic acid 25 (11.0 g, 52.6 mmol), ClCO 2 Et (5.28 ml, 55.2 mmol) and Et 3 N (8.43 ml, 60.5 mmol) in THF (210 ml) was stirred for 1.5 h at room temperature. Under ice-cooling, endo-3-amino-9-benzyl-9-azabicyclo [3.3 .1]-nonane 26a (12.7 g, 55.2 mmol) was added dropwise to the mixture and the resulting mixture was stirred at room temperature for 2.5 d. The reaction mixture was concentrated and water was added to the residue. The solution was adjusted to pH 9 with 10% aqueous K 2 CO 3 . The resulting precipitate was collected by filtration, washed successively with water and ethanol and dried to afford 15.7 g (71%) of 27a as a colorless crystal, which was used in the next step without further purification. MS m/z: 421 (M endo-4-Acetylamino-N-(9-azabicyclo[3.3.1]non-3-yl)-2-methoxybenzamide (28a) A mixture of 27a (15.5 g, 36.8 mmol), acetic acid (20 ml) and Pearlman's catalyst (2.0 g) in MeOH (180 ml) was stirred at room temperature and an atmospheric pressure of H 2 for 1 h. The catalyst was removed by filtration and the filtrate was evaporated. The resulting residue was dissolved in water and the solution was adjusted to pH 9 with 10% aqueous K 2 CO 3 . The resulting precipitate was collected by filtration, washed with water and dried to give 11.7 g (95%) of 28a as a pale yellow crystal, which was recrystallized from 1, 2- Compounds 28b, c were prepared in a manner similar to that described above and their physicochemical data were summarized in Table 2 .
Ethyl endo-3-[(4-Acetylamino-2-methoxybenzoyl)amino]-9-azabicyclo-[3.3.1]nonane-9-acetate (29a) A mixture of 28a (11.6 g, 34.5 mmol), ethyl bromoacetate (4.60 ml, 41.4 mmol) and K 2 CO 3 (5.72 g, 41.4 mmol) in DMF (75 ml) was stirred at 60°C for 2 h. The reaction mixture was poured into water. The resulting precipitate was collected by filtration and washed with water to afford 13.4 g (91%) of 29a as a pale yellow crystal, which was recrystallized from benzene to give colorless prisms, mp 85-88°C. Anal. 22 (3H, s), 2.40-2.65 (2H, m), 3.05-3.30 (2H, m), 3.47 (2H, s), 3.92  (3H, s), 4.15 (2H, q, Jϭ7 Hz), 4.35-4.60 (1H, m) , 6 .83 (1H, dd, Jϭ8.5, (1H, s) .
Compounds 29b, c were prepared in a manner similar to that described above and their physicochemical data were summarized in Table 2 .
Ethyl endo-3-[(4-Acetylamino-5-chloro-2-methoxybenzoyl)amino]-9-azabicyclo[3.3.1]nonnane-9-acetate (30a) The mixture of 29a (13.0 g, 31.1 mmol) and SO 2 Cl 2 (3.42 ml, 34.3 mmol) in CH 2 Cl 2 (140 ml) was stirred at room temperature for 1.5 h. The reaction mixture was basified with aqueous NaHCO 3 28 (3H, s), 2.40-2.65 (2H, m), 3.10-3.35 (2H, m), 3.49 (2H, s) (1H, s) .
Compounds 30b, c were prepared in a manner similar to that described above and physicochemical data were summarized in Table 2 .
Ethyl endo-3-[(4-Amino-5-chloro-2-methoxybenzoyl)amino]-9-azabicyclo[3.3.1]nonane-9-acetate (31a) A mixture of 30a (11.0 g, 24.4 mmol) and 20% ethanolic hydrochloride (66 ml) in EtOH (22 ml) was refluxed for 1 h. The reaction mixture was evaporated and the resulting residue was dissolved in water. The solution was adjusted to pH 10 with K 2 CO 3 . The resulting precipitate was collected by filtration and washed successively with water and iso-Pr 2 O to give 8.88 g (89%) of 31a as a pale brown crystal, which was recrystallized from EtOH to afford colorless needles, mp 163. Compounds 31b, c were prepared in a manner similar to that described above and physicochemical data were summarized in Table 2 . Compounds 32b, c were prepared in a manner similar to that described above and their physicochemical data were summarized in Table 2 . 8 mmol) and trimethylsilyl iodide (22.0 ml, 155 mmol) in CH 2 Cl 2 (400 ml) was stirred at room temperature for 6 h. Sodium hydrogensulfite solution was added to the reaction mixture. The mixture was stirred at room temperature for 15 min and adjusted to pH 2 with 10% HCl. The aqueous layer was basified with K 2 CO 3 and extracted with CH 2 Cl 2 . The extract was washed with water, dried and evaporated to give a yellow brown oil, which was purified by column chromatography [ 0 g ) and acetic acid (25 ml) in MeOH (225 ml) was stirred at room temperature and atmospheric pressure of H 2 for 3 h. The catalyst was removed by filtration and the filtrate was evaporated. The resulting residue was dissolved in 10% HCl and the insoluble substance was removed by filtration. The filtrate was basified with K 2 CO 3 and the precipitate was collected by filtration, washed with water and dried to give 9.90 g (100%) of 41d as a colorless amorphous solid, which was converted to the hydrochloride in the usual manner. Compounds 42e, f were prepared in a manner similar to that described above and their physicochemical data were summarized in Table 3 . Compounds 43e, f were prepared in a manner similar to that described above and their physicochemical data was summarized in Table 3 .
Method E. Methyl 4-[(4-Amino-5-chloro-2-methoxybenzoyl)amino]-1-piperidineacetate (44) To a suspension of 19 (5.00 g, 14.6 mmol) in MeOH (75 ml) was added concentrated sulfuric acid (1.80 g). The mixture was refluxed for 16 h. After cooling, the solvent was evaporated to give the residue, which was basified (pHϭ9) with aqueous K 2 CO 3 and extracted with CH 2 Cl 2 . The extract was washed with saturated aqueous NaCl, dried and evaporated to afford 3.82 g (74%) of 44 as pale brown residue, which was recrystallized from MeOH to afford 2. n-Propyl 4-[(4-Amino-5-chloro-2-methoxybenzoyl)amino]-1-piperidineacetate (45) A solution of n-propyl bromide (1.78 g, 14.5 mmol) in DMF (15 ml) was added to a suspension of 19 (4.50 g, 13.2 mmol) and K 2 CO 3 (2.00 g, 14.5 mol) in DMF (135 ml) at 60°C over 1 h. The mixture was stirred at 60°C for 2 h. After cooling, the reaction mixture was added to water and extracted with toluene. The extract was washed with saturated aqueous NaCl, dried and evaporated to afford colorless residue. The residue was washed with n-heptane to afford 3.94 g (78%) of the crude 45, which was converted to the mesylate in the usual manner. The mesylate of 45 was recrystallized from iso-PrOH to give a colorless crystal, mp 209-210°C. Compounds 46-60 were prepared in a manner similar to that described above and their physicochemical data were summarized in Table 4 .
Pharmacology Gastrointestinal Contractile Activity in Dogs The gastrointestinal motility was measured, according to the method of Z. Itoh et al., in dogs of both sexes, weighing 7.9 to 12.0 kg. Under general anesthesia, a strain-gauge force transducer was chronically sutured on the ascending colon 10 cm distal to the cecum in a direction to measure circular muscle contractions. A sailastic cannula for intravenous (i.v.) or intra-duodenal (i.d.) administration of the tested compound was placed into the superior vena cava or duodenum. The administration of the tested compounds to the dogs was performed more than 2 weeks after the surgery. The tested compounds were solved in saline, including 1% lactic acid, and were intravenously or intra-duodenally administered to the animals more than 2 h after feeding. Gastric motility was expressed as a symbol based on a motor index, representing the area surrounded by the construction wave and the base line during a 20 min period. Colonic motility was expressed as a ratio of the number of dogs, showing giant contractions in the ascending colon during 40 min after the administration, versus the number of tested dogs.
Dopamine D 2 Binding Assay
The test compounds at the concentration of 1-100 mM were tested in binding assays using rat brain synaptic membranes for competition with [ 3 H]Spiperon in the rat striatum at their respective binding sites. Each assay was started by an addition of tissue preparation and terminated by rapid filtration through a Whatman GF/B glass fiber filter under the reduced pressure. The filters were washed three times with 5 ml of ice-cold buffer and transferred to scintillation vials that contained 7 ml of scintillator, and the radioactivity in the filter was counted with a scintillation counter. IC 50 values (the concentration causing 50 inhibition of 3 H-labeled ligand specific binding) of the test compounds were calculated with the equation of Cheng and Prusoff.
5-HT 4 Agonist Activity The esophagus was removed from a male Wister rat, and two preparations, obtained from each animal, was used as a longitudinal preparation. The tissues were mounted in organ baths containing 10 ml of Krebs-Henseleit solution. The bathing medium was maintained at 37°C, pH 7.4, and was equilibrated with a gas mixture consisting of 95% O 2 and 5% CO 2 . An initial tension of 1.0 g was applied and the responses were recorded isometrically with a force-displacement transducer. All preparations were equilibrated for at least 60 min before the start of the experiments. Once the carbachol (10 Ϫ6 M)-induced contractions reached a steady state, drugs were added cumulatively, and relaxation was calculated as a percentage of the initial carbachol-induced force.
Emetic Action in Ferrets Male ferrets, weighing 0.9 to 1.3 kg, and fasted for 16 h, were used. The tested compounds were dissolved with 10% aqueous DMSO solution and were administered orally (p.o.). Then, the incidence of vomiting during the 2 h after the administration was observed.
Physicochemical Stability The tested compounds were dissolved in the pH6.8 buffer solution (Japanese Pharmacopoeia 2nd fluid), and the solution was heated at 37°C for 3 h. The initial concentration of prodrug was 100 mg/ml. The concentration of prodrug that remained was determined by HPLC.
Metabolic Stability with Human Liver S9 The tested compounds were added to human liver S9 (HBI, 0.1 mg protein/ml), pre-incubated at 37°C, and the mixture was incubated at 37°C for 30 min. The initial concentration of prodrug was 1 mmol/l. The concentration of prodrug that remained was determined by HPLC.
Brain Distribution The tested compounds were administrated intravenously to CD-1(ICR) mice (CharlesRiver Japan, male, 10 mg/kg, nϭ4). Blood and brain were taken 2 min after administration. The concentrations of plasma and brain were determined by HPLC or liquid chromatography/ mass spectrometory/mass spectrometory (LC/MS/MS). Brain distribution was estimated from the concentration ratio of each compound in brain to plasma.
